APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tysabri (natalizumab) Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tysabri (natalizumab) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025173 pages

Choose your research edition.

Industry ResearchTysabri (natalizumab) Drug Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Tysabri (natalizumab) Drug Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Tysabri (natalizumab) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tysabri (natalizumab) Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Tysabri (natalizumab) Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Tysabri (natalizumab) Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tysabri (natalizumab) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tysabri (natalizumab) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tysabri (natalizumab) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tysabri (natalizumab) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tysabri (natalizumab) Drug include Biogen and Novartis among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tysabri (natalizumab) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tysabri (natalizumab) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tysabri (natalizumab) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tysabri (natalizumab) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Tysabri (natalizumab) Drug Segment by Company

Biogen

Novartis

Tysabri (natalizumab) Drug Segment by Type

Crohn's Disease

Multiple Sclerosis

Tysabri (natalizumab) Drug Segment by Application

Hospital

Drugs Stores

Tysabri (natalizumab) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tysabri (natalizumab) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tysabri (natalizumab) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tysabri (natalizumab) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tysabri (natalizumab) Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tysabri (natalizumab) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tysabri (natalizumab) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tysabri (natalizumab) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tysabri (natalizumab) Drug Industry Trends Table 2. Tysabri (natalizumab) Drug Industry Drivers Table 3. Tysabri (natalizumab) Drug Industry Opportunities and Challenges Table 4. Tysabri (natalizumab) Drug Industry Restraints Table 5. Global Tysabri (natalizumab) Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tysabri (natalizumab) Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tysabri (natalizumab) Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Tysabri (natalizumab) Drug Sales Market Share by Manufacturers Table 9. Global Tysabri (natalizumab) Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Tysabri (natalizumab) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tysabri (natalizumab) Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tysabri (natalizumab) Drug Manufacturers, Product Type & Application Table 13. Global Tysabri (natalizumab) Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tysabri (natalizumab) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Crohn's Disease Table 17. Major Manufacturers of Multiple Sclerosis Table 18. Global Tysabri (natalizumab) Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Tysabri (natalizumab) Drug Sales by Type (2021-2026) & (k units) Table 20. Global Tysabri (natalizumab) Drug Sales by Type (2027-2032) & (k units) Table 21. Global Tysabri (natalizumab) Drug Sales Market Share by Type (2021-2026) Table 22. Global Tysabri (natalizumab) Drug Sales Market Share by Type (2027-2032) Table 23. Global Tysabri (natalizumab) Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Tysabri (natalizumab) Drug Revenue by Type (2021-2026) & (k units) Table 25. Global Tysabri (natalizumab) Drug Revenue by Type (2027-2032) & (k units) Table 26. Global Tysabri (natalizumab) Drug Revenue Market Share by Type (2021-2026) Table 27. Global Tysabri (natalizumab) Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Drugs Stores Table 30. Global Tysabri (natalizumab) Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Tysabri (natalizumab) Drug Sales by Application (2021-2026) & (k units) Table 32. Global Tysabri (natalizumab) Drug Sales by Application (2027-2032) & (k units) Table 33. Global Tysabri (natalizumab) Drug Sales Market Share by Application (2021-2026) Table 34. Global Tysabri (natalizumab) Drug Sales Market Share by Application (2027-2032) Table 35. Global Tysabri (natalizumab) Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Tysabri (natalizumab) Drug Revenue by Application (2021-2026) & (k units) Table 37. Global Tysabri (natalizumab) Drug Revenue by Application (2027-2032) & (k units) Table 38. Global Tysabri (natalizumab) Drug Revenue Market Share by Application (2021-2026) Table 39. Global Tysabri (natalizumab) Drug Revenue Market Share by Application (2027-2032) Table 40. Global Tysabri (natalizumab) Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Tysabri (natalizumab) Drug Sales by Region (2021-2026) & (k units) Table 42. Global Tysabri (natalizumab) Drug Sales Market Share by Region (2021-2026) Table 43. Global Tysabri (natalizumab) Drug Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Tysabri (natalizumab) Drug Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Tysabri (natalizumab) Drug Sales by Country (2021-2026) & (k units) Table 47. North America Tysabri (natalizumab) Drug Sales by Country (2027-2032) & (k units) Table 48. Europe Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Tysabri (natalizumab) Drug Sales by Country (2021-2026) & (k units) Table 50. Europe Tysabri (natalizumab) Drug Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Tysabri (natalizumab) Drug Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Tysabri (natalizumab) Drug Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Tysabri (natalizumab) Drug Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Tysabri (natalizumab) Drug Sales by Country (2027-2032) & (k units) Table 57. Global Tysabri (natalizumab) Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Tysabri (natalizumab) Drug Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Tysabri (natalizumab) Drug Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Tysabri (natalizumab) Drug Revenue Market Share by Region (2021-2026) Table 61. Global Tysabri (natalizumab) Drug Revenue Market Share by Region (2027-2032) Table 62. Biogen Company Information Table 63. Biogen Business Overview Table 64. Biogen Tysabri (natalizumab) Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Biogen Tysabri (natalizumab) Drug Product Portfolio Table 66. Biogen Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Tysabri (natalizumab) Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis Tysabri (natalizumab) Drug Product Portfolio Table 71. Novartis Recent Development Table 72. Key Raw Materials Table 73. Raw Materials Key Suppliers Table 74. Tysabri (natalizumab) Drug Distributors List Table 75. Tysabri (natalizumab) Drug Customers List Table 76. Research Programs/Design for This Report Table 77. Authors List of This Report Table 78. Secondary Sources Table 79. Primary Sources List of Figures Figure 1. Tysabri (natalizumab) Drug Product Image Figure 2. Global Tysabri (natalizumab) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tysabri (natalizumab) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Tysabri (natalizumab) Drug Sales (2021-2032) & (k units) Figure 5. Global Tysabri (natalizumab) Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tysabri (natalizumab) Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Crohn's Disease Image Figure 9. Multiple Sclerosis Image Figure 10. Global Tysabri (natalizumab) Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Tysabri (natalizumab) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Tysabri (natalizumab) Drug Sales Market Share by Type (2021-2032) Figure 13. Global Tysabri (natalizumab) Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Tysabri (natalizumab) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Tysabri (natalizumab) Drug Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Drugs Stores Image Figure 18. Global Tysabri (natalizumab) Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Tysabri (natalizumab) Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Tysabri (natalizumab) Drug Sales Market Share by Application (2021-2032) Figure 21. Global Tysabri (natalizumab) Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Tysabri (natalizumab) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Tysabri (natalizumab) Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Tysabri (natalizumab) Drug Sales Market Share by Country (2021-2032) Figure 26. U.S. Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Tysabri (natalizumab) Drug Sales Market Share by Country (2021-2032) Figure 31. Germany Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Tysabri (natalizumab) Drug Sales Market Share by Country (2021-2032) Figure 38. China Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Tysabri (natalizumab) Drug Sales Market Share by Country (2021-2032) Figure 46. Brazil Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Tysabri (natalizumab) Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Tysabri (natalizumab) Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Tysabri (natalizumab) Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Tysabri (natalizumab) Drug Revenue (2021-2032) & (US$ Million) Figure 57. North America Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Tysabri (natalizumab) Drug Revenue (2021-2032) & (US$ Million) Figure 59. Europe Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Tysabri (natalizumab) Drug Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Tysabri (natalizumab) Drug Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Tysabri (natalizumab) Drug Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Tysabri (natalizumab) Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Crohn's Disease
  • Multiple Sclerosis
Applications
  • Hospital
  • Drugs Stores
Companies covered
  • Biogen
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tysabri (natalizumab) Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tysabri (natalizumab) Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tysabri (natalizumab) Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tysabri (natalizumab) Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tysabri (natalizumab) Drug Market Dynamics
  1. 2.1 Tysabri (natalizumab) Drug Industry Trends
  2. 2.2 Tysabri (natalizumab) Drug Industry Drivers
  3. 2.3 Tysabri (natalizumab) Drug Industry Opportunities and Challenges
  4. 2.4 Tysabri (natalizumab) Drug Industry Restraints
3 Tysabri (natalizumab) Drug Market by Manufacturers
  1. 3.1 Global Tysabri (natalizumab) Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tysabri (natalizumab) Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tysabri (natalizumab) Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tysabri (natalizumab) Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tysabri (natalizumab) Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tysabri (natalizumab) Drug Manufacturers, Product Type & Application
  7. 3.7 Global Tysabri (natalizumab) Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tysabri (natalizumab) Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tysabri (natalizumab) Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tysabri (natalizumab) Drug Tier 1, Tier 2, and Tier 3
4 Tysabri (natalizumab) Drug Market by Type
  1. 4.1 Tysabri (natalizumab) Drug Type Introduction
  2. 4.1.1 Crohn's Disease
  3. 4.1.2 Multiple Sclerosis
  4. 4.2 Global Tysabri (natalizumab) Drug Sales by Type
  5. 4.2.1 Global Tysabri (natalizumab) Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tysabri (natalizumab) Drug Sales by Type (2021-2032)
  7. 4.2.3 Global Tysabri (natalizumab) Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global Tysabri (natalizumab) Drug Revenue by Type
  9. 4.3.1 Global Tysabri (natalizumab) Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tysabri (natalizumab) Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global Tysabri (natalizumab) Drug Revenue Market Share by Type (2021-2032)
5 Tysabri (natalizumab) Drug Market by Application
  1. 5.1 Tysabri (natalizumab) Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Stores
  4. 5.2 Global Tysabri (natalizumab) Drug Sales by Application
  5. 5.2.1 Global Tysabri (natalizumab) Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Tysabri (natalizumab) Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Tysabri (natalizumab) Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Tysabri (natalizumab) Drug Revenue by Application
  9. 5.3.1 Global Tysabri (natalizumab) Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Tysabri (natalizumab) Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Tysabri (natalizumab) Drug Revenue Market Share by Application (2021-2032)
6 Global Tysabri (natalizumab) Drug Sales by Region
  1. 6.1 Global Tysabri (natalizumab) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tysabri (natalizumab) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Tysabri (natalizumab) Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Tysabri (natalizumab) Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tysabri (natalizumab) Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tysabri (natalizumab) Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tysabri (natalizumab) Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tysabri (natalizumab) Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tysabri (natalizumab) Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tysabri (natalizumab) Drug Revenue by Region
  1. 7.1 Global Tysabri (natalizumab) Drug Revenue by Region
  2. 7.1.1 Global Tysabri (natalizumab) Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tysabri (natalizumab) Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Tysabri (natalizumab) Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Tysabri (natalizumab) Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tysabri (natalizumab) Drug Revenue (2021-2032)
  8. 7.2.2 North America Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tysabri (natalizumab) Drug Revenue (2021-2032)
  11. 7.3.2 Europe Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tysabri (natalizumab) Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tysabri (natalizumab) Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tysabri (natalizumab) Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Tysabri (natalizumab) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Tysabri (natalizumab) Drug Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Tysabri (natalizumab) Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Tysabri (natalizumab) Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tysabri (natalizumab) Drug Value Chain Analysis
  2. 9.1.1 Tysabri (natalizumab) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tysabri (natalizumab) Drug Production Mode & Process
  6. 9.2 Tysabri (natalizumab) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tysabri (natalizumab) Drug Distributors
  9. 9.2.3 Tysabri (natalizumab) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst